The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Open accessAbstract
In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“In the MSK-IMPACT trial, this proportion was also 11% [53].”
BackgroundBurtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · cited 1×
“Various guidelines can be used as a reference for details on how to deal with each organ [39].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70311-0 · Cited by 1,978
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · cited 1×
“The importance of drug epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence, and epigenetic dysregulation is often related to human diseases, especially cancer [68].”
BackgroundChung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L., & Kobayashi, H. (2011) · Nature Medicine · doi:10.1038/nm.2554 · Cited by 1,057
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.04.008 · Cited by 804
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Immunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 668
Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2587 · Cited by 572
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513
Near-Infrared Photoimmunotherapy of Cancer
Kobayashi, H., & Choyke, P. L. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00273 · Cited by 479
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30421-7 · Cited by 428
Sunami, K., Ichikawa, H., Kubo, T., Kato, M., Fujiwara, Y., Shimomura, A., Koyama, T., Kakishima, H., Kitami, M., Matsushita, H., et al. (2019) · Cancer Science · doi:10.1111/cas.13969 · Cited by 378
Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y.-H., Catalano, P. S., Lako, A., Ciantra, Z., Weirather, J. L., Criscitiello, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2955 · Cited by 361
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Hitt, R., Irigoyen, A., Cortes-Funes, H., Grau, J. J., García-Sáenz, J. A., & Cruz-Hernandez, J. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr367 · Cited by 223
Magrini, S. M., Buglione, M., Corvò, R., Pirtoli, L., Paiar, F., Ponticelli, P., Petrucci, A., Bacigalupo, A., Crociani, M., Lastrucci, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1671 · Cited by 214
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210
Cognetti, D. M., Johnson, J. M., Curry, J. M., Kochuparambil, S. T., McDonald, D., Mott, F., Fidler, M. J., Stenson, K., Vasan, N. R., Razaq, M. A., et al. (2021) · Head & Neck · doi:10.1002/hed.26885 · Cited by 186
Saleh, K., Daste, A., Martin, N., Pons-Tostivint, E., Auperin, A., Herrera-Gomez, R. G., Baste-Rotllan, N., Bidault, F., Guigay, J., Le Tourneau, C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.026 · Cited by 184
Castilho, R., Squarize, C., & Almeida, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071506 · Cited by 183
Normanno, N., Maiello, M. R., & Luca, A. D. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10194 · Cited by 157
Georgiadis, A. P., Durham, J. N., Keefer, L. A., Bartlett, B. R., Zielonka, M., Murphy, D. M., White, J. R., Lu, S., Verner, E. L., Ruan, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1372 · Cited by 151
Guigay, J., Fayette, J., Dillies, A.-F., Sire, C., Kerger, J. N., Tennevet, I., Machiels, J.-P., Zanetta, S., Pointreau, Y., Moal, L. B. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv268 · Cited by 150
Kobayashi, H., Furusawa, A., Rosenberg, A., & Choyke, P. L. (2020) · International Immunology · doi:10.1093/intimm/dxaa037 · Cited by 149
Glisson, B. S., Murphy, B. A., Frenette, G., Khuri, F. R., & Forastiere, A. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1593 · Cited by 136
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 105
Haigentz, M., Kim, M., Sarta, C., Lin, J., Keresztes, R. S., Culliney, B. E., Gaba, A. G., Smith, R. V., Shapiro, G. I., Chirieac, L. R., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.024 · Cited by 90
Tahara, M., Kiyota, N., Yokota, T., Hasegawa, Y., Muro, K., Takahashi, S., Onoe, T., Homma, A., Taguchi, J., Suzuki, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy040 · Cited by 89
Apolo, A. B., Ellerton, J. A., Infante, J. R., Agrawal, M., Gordon, M. S., Aljumaily, R. M., Gourdin, T. S., Dirix, L. Y., Lee, K., Taylor, M. H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001246 · Cited by 88
Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
Gomes-da-Silva, L. C., Kepp, O., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1841393 · Cited by 88
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
Szturz, P., & Vermorken, J. B. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104492 · Cited by 86
Raghav, K. P. S., Morris, V. K., Tang, C. Z., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B. M., Overman, M. J., Shaw, K. R. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10559 · Cited by 81
Muro, K., Yoshino, T., Doi, T., Shirao, K., Takiuchi, H., Hamamoto, Y., Watanabe, H., Yang, B.-B., & Asahi, D. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp016 · Cited by 63
Nishinaga, Y., Sato, K., Yasui, H., Taki, S., Takahashi, K., Shimizu, M., Endo, R., Koike, C., Kuramoto, N., Nakamura, S., et al. (2020) · Cells · doi:10.3390/cells9041019 · Cited by 62
Pestana, R. C., Becnel, M., Rubin, M. L., Torman, D., Crespo, J., Phan, J., Hanna, E. Y., Bell, D., Glisson, B. S., Johnson, J. M., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104523 · Cited by 61
AMG 510 First to Inhibit “Undruggable” KRAS
(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-073 · Cited by 47
Implementation of “clinical sequencing” in cancer genome medicine in Japan
Kohno, T. (2017) · Cancer Science · doi:10.1111/cas.13486 · Cited by 40
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
Bregni, G., Sciallero, S., & Sobrero, A. F. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7229 · Cited by 40
Kacew, A. J., Harris, E. J., Lorch, J. H., Schoenfeld, J. D., Margalit, D. N., Kass, J. I., Tishler, R. B., Haddad, R. I., & Hanna, G. J. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104676 · Cited by 32
Cognetti, D. M., Johnson, J. M., Curry, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6014 · Cited by 29
Oyama, R., Kito, F., Takahashi, M., Hattori, E., Noguchi, R., Takai, Y., Sakumoto, M., Qiao, Z., Toki, S., Sugawara, M., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1128-z · Cited by 14
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Metadata
- Authors
- Kitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-12-29
- Volume
- 22
- Issue
- 1
- Pages
- 240
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3115235573
- Cited by
- 256
- References
- 64
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.